Gujarat Themis Biosyn Ltd vs Mankind Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 378.6 as of 06 May 15:30 . The P/E Ratio of Gujarat Themis Biosyn Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Mankind Pharma Ltd changed from 48.1 on March 2024 to 50.2 on March 2025 . This represents a CAGR of 2.16% over 2 years The Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Mankind Pharma Ltd changed from ₹ 92029 crore on March 2024 to ₹ 99973 crore on March 2025 . This represents a CAGR of 4.23% over 2 years The revenue of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Mankind Pharma Ltd for the Dec '25 is ₹ 3643 crore as compare to the Sep '25 revenue of ₹ 3791 crore. This represent the decline of -3.91% The ebitda of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Mankind Pharma Ltd for the Dec '25 is ₹ 888.8 crore as compare to the Sep '25 ebitda of ₹ 1015 crore. This represent the decline of -12.48% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Mankind Pharma Ltd changed from ₹ 543.07 crore to ₹ 413.88 crore over 7 quarters. This represents a CAGR of -14.38% The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 yearsThe Dividend Payout of Mankind Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Mankind Pharma Ltd

Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company with the name 'Mankind Pharma Private Limited', by the Registrar of Companies, Delhi and Haryana, at New Delhi.
Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to 'Mankind Pharma Limited' and the RoC issued a fresh Certificate of Incorporation on April 13, 2006. The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products.
It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Mankind Pharma Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Mankind Pharma Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 4,125 Cr while Market cap of Mankind Pharma Ltd is 97,505 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Mankind Pharma Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Mankind Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Mankind Pharma Ltd?

As of May 6, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹378.6. On the other hand, Mankind Pharma Ltd stock price is INR ₹2361.9.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Mankind Pharma Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Mankind Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.